Brain metastases originating in breast cancer: clinical-pathological analysis and immunohistochemical profile.

التفاصيل البيبلوغرافية
العنوان:	Brain metastases originating in breast cancer: clinical-pathological analysis and immunohistochemical profile.
المؤلفون:	Sava A; Department of Surgery II, Faculty of Medicine, Doctoral School, Grigore T. Popa University of Medicine and Pharmacy, Iaşi, Romania; costea10@yahoo.com, ruxandravatavu@yahoo.com., Costea CF, Vatavu R, Grigore M, Turliuc MD, Dumitrescu GF, Eva L, Motoc AGM, Stan CI, Gavril LC, Scripcariu SI
المصدر:	Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie [Rom J Morphol Embryol] 2021 Apr-Jun; Vol. 62 (2), pp. 435-444.
نوع المنشور:	Journal Article
اللغة:	English
بيانات الدورية:	Publisher: Editura Academiei Române Country of Publication: Romania NLM ID: 9112454 Publication Model: Print Cited Medium: Internet ISSN: 2066-8279 (Electronic) Linking ISSN: 12200522 NLM ISO Abbreviation: Rom J Morphol Embryol Subsets: MEDLINE
أسماء مطبوعة:	Original Publication: Bucuresti, România : Editura Academiei Române, [1990-
مواضيع طبية MeSH:	Brain Neoplasms/secondary , Breast Neoplasms/pathology, Female ; Humans ; Middle Aged ; Receptor, ErbB-2 ; Receptors, Estrogen ; Receptors, Progesterone ; Retrospective Studies
مستخلص:	The incidence of brain metastases (BMs) originating in breast cancer (BC) is increasing due to advances in imaging techniques, which can detect such events early, and due to new therapies that can ensure longer survival. We performed a retrospective study on patients with BMs originating in BC and receiving surgical treatment in Neurosurgery Clinics of Prof. Dr. Nicolae Oblu Emergency Clinical Hospital, Iaşi, Romania, from January 2018 to December 2019. We identified 10 consecutive patients who underwent a craniotomy for a BMs originating in a BC (either for diagnostic purpose or with therapeutic intent). Clinicopathological data were collected from the electronic medical record and included the patient demographics (age at diagnosis of their BM), morphological characteristics of BM [location, cytopathological features, histopathological (HP) subtype, and immunohistochemical features, i.e., cytokeratin 5∕6 (CK5∕6), mammaglobin, estrogen receptor (ER), progesterone receptor (PR), and Ki67 labeling index (LI)], and time from BC diagnosis to BM diagnosis. Ninety percent of patients were in their sixth and seventh decades of life, with a median age of 57.9 years (47-65 years). Median time from BC diagnosis to BM was 34.42 months. Fifty percent of BMs were located in the parietal lobes, and 70% of all cases have multiple (≥2) BMs. All cases (100%) had a cytopathological examination, showing a hypercellular pattern, with poorly cohesive clusters of mild or pleomorphic cells, with nuclei with homogeneously distributed fine granular chromatin membrane, and with small or enlarged and irregular nucleoli. The dominant histopathology was invasive breast carcinoma of no special type (IBC-NST) (70%), but we also identified specific subtypes, i.e., tubular carcinoma (TC) (20%) and invasive micropapillary carcinoma (IMPC) (10%). Correlating location with HP subtypes of BMs from BC, IBC-NST and IMPC were located mostly in parietal lobes, and TC developed only in the occipital lobe. We found three patterns of immunostaining: (i) CK5∕6 +∕-, mammaglobin+, ER+, PR-, which was much more characteristic for IBC-NST; (ii) CK5∕6-, mammaglobin+, ER-, PR-, being identified in tubular breast carcinoma; (iii) CK5∕6 +∕-, mammaglobin-, ER-, PR-, which were revealed by invasive micropapillary breast carcinoma. Our study revealed the fact that BMs originating in BC show heterogeneity of hormone receptor status, although morphologically there is not so much diversity. We also found a very variable Ki67 LI, which correlated especially with the morphological subtype.
References:	Asian Pac J Cancer Prev. 2016;17(S3):43-6. (PMID: 27165206) Br J Cancer. 2014 Jul 29;111(3):619-22. (PMID: 24921921) Oncologist. 2015 May;20(5):466-73. (PMID: 25802405) Expert Rev Anticancer Ther. 2014 Feb;14(2):173-83. (PMID: 24308683) J Neurooncol. 2016 May;127(3):407-14. (PMID: 26909695) Oncotarget. 2017 Feb 2;8(31):50774-50781. (PMID: 28881602) Sci Rep. 2019 Jan 22;9(1):286. (PMID: 30670771) Cancer Manag Res. 2019 Nov 01;11:9331-9338. (PMID: 31802951) J Breast Health. 2015 Apr 1;11(2):59-66. (PMID: 28331693) J Clin Oncol. 2004 Sep 1;22(17):3608-17. (PMID: 15337811) Cancers (Basel). 2020 Jul 31;12(8):. (PMID: 32751846) BMC Res Notes. 2018 Jul 31;11(1):531. (PMID: 30064485) Cancer. 2006 Aug 15;107(4):696-704. (PMID: 16826579) Rom J Morphol Embryol. 2013;54(3):649-53. (PMID: 24068419) Breast. 2010 Jun;19(3):231-7. (PMID: 20304650) Patholog Res Int. 2010 Dec 16;2011:549847. (PMID: 21209717) Breast Cancer Res. 2019 May 10;21(1):60. (PMID: 31077239) Rom J Morphol Embryol. 2020;61(1):81-93. (PMID: 32747898) Nature. 2000 Aug 17;406(6797):747-52. (PMID: 10963602) Ann Med Surg (Lond). 2019 Dec 06;49:44-48. (PMID: 31890196) Ann Oncol. 2011 Aug;22(8):1736-47. (PMID: 21709140) Surg Neurol Int. 2013 May 02;4(Suppl 4):S192-202. (PMID: 23717790) PLoS One. 2017 Nov 20;12(11):e0188542. (PMID: 29155879) Cancer. 2008 Nov 15;113(10):2638-45. (PMID: 18833576) Breast Cancer Res. 2016 Jan 19;18(1):8. (PMID: 26781299) Onkologie. 2010;33(4):143-4. (PMID: 20389139) Histopathology. 2020 Aug;77(2):181-185. (PMID: 32056259) Rom J Morphol Embryol. 2017;58(1):21-26. (PMID: 28523293) Oncotarget. 2020 Feb 11;11(6):650-669. (PMID: 32110283) Brain. 2013 Jan;136(Pt 1):330-42. (PMID: 22945964) Asian J Surg. 2015 Oct;38(4):220-3. (PMID: 26216259) Clin Oncol (R Coll Radiol). 2004 Apr;16(2):119-24. (PMID: 15074735) PLoS One. 2014 Feb 24;9(2):e89389. (PMID: 24586742)
المشرفين على المادة:	0 (Receptors, Estrogen) 0 (Receptors, Progesterone) EC 2.7.10.1 (Receptor, ErbB-2)
تواريخ الأحداث:	Date Created: 20220113 Date Completed: 20220117 Latest Revision: 20220531
رمز التحديث:	20240628
مُعرف محوري في PubMed:	PMC8848228
DOI:	10.47162/RJME.62.2.09
PMID:	35024731
قاعدة البيانات:	MEDLINE

الوصف
تدمد:	2066-8279
DOI:	10.47162/RJME.62.2.09